Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine

Volumn 7, Issue 1, 2013, Pages 13-17

  Robinson, Douglas S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

asthma; eosinophil; mepolizumab; severe asthma

Indexed keywords

MEPOLIZUMAB; NITRIC OXIDE;

ASTHMA; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ASTHMA; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; NOTE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT DURATION;

EID: 84873120214     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.84     Document Type: Note

References (29)

1. Turner S, Paton J, Higgins B, Douglas G; British Guidelines on the Management of Asthma. British guidelines on the management of asthma: what's new for 2011? Thorax 66(12), 1104-1105 (2011).
2. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 365(9463), 974-976 (2005). (Pubitemid 41071432)
3. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF; Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treat asthma. Eur. Respir. J. 22(3), 478-483 (2003).
4. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am. J. Respir. Crit. Care Med. 180(9), 817-822 (2009).
5. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178(3), 218-224 (2008).
6. Moore WC, Meyers DA, Wenzel SE et al.; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181(4), 315-323 (2010).
7. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180(5), 388-395 (2009).
8. Robinson DS. The role of the T cell in asthma. J. Allergy Clin. Immunol. 126(6), 1081-1091; quiz 1092 (2010).
9. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360(9347), 1715-1721 (2002). (Pubitemid 35447900)
10. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144-2148 (2000).
11. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167(2), 199-204 (2003). (Pubitemid 36076080)
12. Flood-Page P, Swenson C, Faiferman I et al.; International mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176(11), 1062-1071 (2007). (Pubitemid 350223751)
13. Castro M, Mathur S, Hargreave F et al.; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184(10), 1125-1132 (2011).
14. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360(10), 973-984 (2009).
15. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360(10), 985-993 (2009).
16. Robinson DS. Mepolizumab treatment for asthma. Expert Opin. Biol. Ther. 13(2), 295-302 (2013).
17. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842), 651-659 (2012).
18. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112(7), 1029-1036 (2003). (Pubitemid 38056318)
19. Lemière C, Ernst P, Olivenstein R et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J. Allergy Clin. Immunol. 118(5), 1033-1039 (2006). (Pubitemid 44666987)
20. Macedo P, Hew M, Torrego A et al. Inflammatory biomarkers in airways ofpatients with severe asthma compared with non-severe asthma. Clin. Exp. Allergy 39(11), 1668-1676 (2009).
21. Jia G, Erickson RW, Choy DF et al.; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 130(3), 647-654.e10 (2012).
22. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365(12), 1088-1098 (2011).
23. Tan R, Corren J. Omalizumab in the treatment of asthma. Expert Rev. Respir. Med. 5(6), 747-756 (2011).
24. Castro M, Rubin AS, Laviolette M et al.; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med. 181(2), 116-124 (2010).
25. Bel EH, Sousa A, Fleming L et al.; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 66(10), 910-917 (2011).
26. Sweeney J, Brightling CE, Menzies-Gow A, Niven R, Patterson CC, Heaney LG; British Thoracic Society Difficult Asthma Network. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax 67(8), 754-756 (2012).
27. Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125(6), 1237-1244.e2 (2010).
28. Asthma UK -What is severe asthma? www.asthma.org.uk/about-asthma/what- issevere-asthma
29. Asthma (severe, persistent, patients aged 6+, adults) -omazilumab. http://guidance.nice.org.uk/TA/WaveR/ 110/Consultation/Latest